{ "run": { "id": "cmnr148g104dop6587imwyb4k", "region": "US", "assetId": "cmnr148f404dkp658kthsz1yl", "ticker": "IDXX", "snapshotId": "cmnr148fj04dmp658o5rsg469", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:07.773Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr148fj04dmp658o5rsg469", "assetId": "cmnr148f404dkp658kthsz1yl", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 591.84, "dayLow": 588.43, "volume": 442366, "dayHigh": 605.82, "currency": "USD", "prevClose": 574.8, "week52Low": 356.14, "week52High": 769.98 }, "fundamentals": { "pe": 51.3690205011389, "beta": 1.18209462549933, "epsTTM": 13.17, "fcfTTM": 1002365000, "growth": { "epsYoy": 0.222841225626741, "revenueYoy": 0.1042200341551927 }, "sector": "In Vitro & In Vivo Diagnostic Substances", "margins": { "net": 0.246175037212149, "gross": 0.6179747110743262, "operating": 0.316014212879981 }, "website": null, "industry": null, "pegRatio": 2.30518479498861, "ebitdaTTM": 1410997000, "forwardPe": 46.5929752066116, "marketCap": 42899749759, "totalCash": 180070000, "totalDebt": 524995000, "debtEquity": 0.32702165153113, "quickRatio": 0.6375688318561578, "revenueTTM": 4303702000, "companyName": "IDEXX LABORATORIES INC /DE", "priceToBook": 33.8930201142033, "currentRatio": 1.230683992360817, "dividendYield": null, "returnOnAssets": 0.3161862730205306, "returnOnEquity": 0.6599446985548, "analystOpinions": null, "businessSummary": null, "enterpriseValue": 54756203310, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": null, "sharesOutstanding": 79624034, "enterpriseToEbitda": 38.80674679676853, "analystTargetMedian": null, "enterpriseToRevenue": 12.72304711385686, "operatingCashflowTTM": 1181805000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:07.759Z" }, "results": [ { "id": "cmnr148g304dqp658tlppylci", "runId": "cmnr148g104dop6587imwyb4k", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-sonnet-4-20250514\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"IDXX\",\"currency\":\"USD\",\"current_price\":591.84,\"target_price_6m\":610,\"target_price_12m\":625,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Premium veterinary diagnostics compounder with 61.8% gross margins\",\"Recurring revenue model supports durable mid-to-high single-digit organic growth\",\"Valuation at 51x trailing P/E already prices in strong execution\",\"EPS growth of 22% YoY may decelerate as comps normalize\",\"Stock sits mid-range of 52-week band; limited near-term catalyst visibility\"],\"key_drivers\":[{\"driver\":\"Recurring CAG diagnostic revenue growth driven by installed instrument base\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion toward mid-30s% over time\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple susceptible to growth deceleration\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"International market penetration (clinical visits and diagnostics per visit)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Software & digital platform investments supporting retention\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pet population and wellness visit trends post-pandemic normalizing\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Share buybacks supporting EPS growth (low share count ~80M)\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Rising interest rates impacting growth stock multiples\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Multiple compression if revenue growth decelerates below high-single-digits\",\"Macroeconomic weakness reducing discretionary vet visits\",\"Competitive threats from Mars/Heska or new entrants in point-of-care diagnostics\",\"PEG ratio of 2.3x suggests limited margin of safety at current valuation\",\"Regulatory or reimbursement changes in key veterinary markets\"],\"assumptions\":{\"revenue_cagr_3y\":0.09,\"ebit_margin_target\":0.33,\"wacc\":0.095,\"terminal_multiple\":35},\"scenarios\":{\"bear\":{\"target_price\":475,\"prob\":0.2,\"notes\":\"Growth slows to mid-single-digits; P/E compresses to ~35x on ~$13.50 EPS.\"},\"base\":{\"target_price\":625,\"prob\":0.55,\"notes\":\"~13% EPS growth to ~$14.90; modest P/E compression to ~42x.\"},\"bull\":{\"target_price\":745,\"prob\":0.25,\"notes\":\"Sustained double-digit growth; P/E holds near 48x on ~$15.50 EPS.\"}},\"method_notes\":\"Earnings-power model: TTM EPS of $13.17 grown forward 12M at 12-15% based on revenue CAGR and margin expansion assumptions; applied scenario-weighted P/E multiples (35-48x). Base 12M target of $625 implies ~5.6% upside, within HOLD threshold given elevated valuation and moderate uncertainty. EV/EBIT terminal anchor of 35x used for DCF cross-check. No sell-side targets used as numeric inputs. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "claude-sonnet-4-20250514", "risks": [ "Multiple compression if revenue growth decelerates below high-single-digits", "Macroeconomic weakness reducing discretionary vet visits", "Competitive threats from Mars/Heska or new entrants in point-of-care diagnostics", "PEG ratio of 2.3x suggests limited margin of safety at current valuation", "Regulatory or reimbursement changes in key veterinary markets" ], "ticker": "IDXX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "~13% EPS growth to ~$14.90; modest P/E compression to ~42x.", "target_price": 625 }, "bear": { "prob": 0.2, "notes": "Growth slows to mid-single-digits; P/E compresses to ~35x on ~$13.50 EPS.", "target_price": 475 }, "bull": { "prob": 0.25, "notes": "Sustained double-digit growth; P/E holds near 48x on ~$15.50 EPS.", "target_price": 745 } }, "confidence": 0.62, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.09, "terminal_multiple": 35, "ebit_margin_target": 0.33 }, "key_drivers": [ { "driver": "Recurring CAG diagnostic revenue growth driven by installed instrument base", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion toward mid-30s% over time", "impact": "MED", "direction": "POS" }, { "driver": "Premium valuation multiple susceptible to growth deceleration", "impact": "HIGH", "direction": "NEG" }, { "driver": "International market penetration (clinical visits and diagnostics per visit)", "impact": "MED", "direction": "POS" }, { "driver": "Software & digital platform investments supporting retention", "impact": "MED", "direction": "POS" }, { "driver": "Pet population and wellness visit trends post-pandemic normalizing", "impact": "MED", "direction": "NEG" }, { "driver": "Share buybacks supporting EPS growth (low share count ~80M)", "impact": "LOW", "direction": "POS" }, { "driver": "Rising interest rates impacting growth stock multiples", "impact": "MED", "direction": "NEG" } ], "method_notes": "Earnings-power model: TTM EPS of $13.17 grown forward 12M at 12-15% based on revenue CAGR and margin expansion assumptions; applied scenario-weighted P/E multiples (35-48x). Base 12M target of $625 implies ~5.6% upside, within HOLD threshold given elevated valuation and moderate uncertainty. EV/EBIT terminal anchor of 35x used for DCF cross-check. No sell-side targets used as numeric inputs. Not investment advice.", "current_price": 591.84, "recommendation": "HOLD", "thesis_bullets": [ "Premium veterinary diagnostics compounder with 61.8% gross margins", "Recurring revenue model supports durable mid-to-high single-digit organic growth", "Valuation at 51x trailing P/E already prices in strong execution", "EPS growth of 22% YoY may decelerate as comps normalize", "Stock sits mid-range of 52-week band; limited near-term catalyst visibility" ], "target_price_6m": 610, "target_price_12m": 625 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 38032, "createdAt": "2026-04-09T05:21:07.773Z", "usage": { "inputTokens": 3506, "outputTokens": 1753, "costUsd": 0.061355 } }, { "id": "cmnr148g304dtp658mxu02q6x", "runId": "cmnr148g104dop6587imwyb4k", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearchAnalystModel\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IDXX\",\n \"currency\": \"USD\",\n \"current_price\": 591.84,\n \"target_price_6m\": 620.0,\n \"target_price_12m\": 640.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Strong growth in veterinary diagnostics market.\",\n \"High margins and profitability sustained.\",\n \"Premium valuation from market leadership.\",\n \"Innovation drives product expansion.\",\n \"Balanced by competition and regulatory risks.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Pet ownership and healthcare spending\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operational efficiency improvements\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive landscape intensifying\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Regulatory environment changes\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Technological advancements in diagnostics\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Economic cycles affecting spending\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"International expansion opportunities\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Pricing power from brand strength\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Intense competition in diagnostics sector\",\n \"Regulatory hurdles for new products\",\n \"Economic downturn reducing pet care spending\",\n \"Valuation multiple compression risk\",\n \"Supply chain disruptions\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.10,\n \"ebit_margin_target\": 0.32,\n \"wacc\": 0.08,\n \"terminal_multiple\": 25.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 550.0, \"prob\": 0.2, \"notes\": \"Growth slows and multiples compress due to competition.\" },\n \"base\": { \"target_price\": 640.0, \"prob\": 0.6, \"notes\": \"Steady growth with stable valuation from leadership.\" },\n \"bull\": { \"target_price\": 720.0, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion from innovation.\" }\n },\n \"method_notes\": \"Simplified DCF using growth and margin assumptions; BUY due to 8% upside, balanced risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearchAnalystModel", "risks": [ "Intense competition in diagnostics sector", "Regulatory hurdles for new products", "Economic downturn reducing pet care spending", "Valuation multiple compression risk", "Supply chain disruptions" ], "ticker": "IDXX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady growth with stable valuation from leadership.", "target_price": 640 }, "bear": { "prob": 0.2, "notes": "Growth slows and multiples compress due to competition.", "target_price": 550 }, "bull": { "prob": 0.2, "notes": "Accelerated growth and multiple expansion from innovation.", "target_price": 720 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.1, "terminal_multiple": 25, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "Pet ownership and healthcare spending", "impact": "HIGH", "direction": "POS" }, { "driver": "Operational efficiency improvements", "impact": "MED", "direction": "POS" }, { "driver": "Competitive landscape intensifying", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory environment changes", "impact": "LOW", "direction": "NEG" }, { "driver": "Technological advancements in diagnostics", "impact": "HIGH", "direction": "POS" }, { "driver": "Economic cycles affecting spending", "impact": "MED", "direction": "NEG" }, { "driver": "International expansion opportunities", "impact": "MED", "direction": "POS" }, { "driver": "Pricing power from brand strength", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Simplified DCF using growth and margin assumptions; BUY due to 8% upside, balanced risks. Not investment advice.", "current_price": 591.84, "recommendation": "BUY", "thesis_bullets": [ "Strong growth in veterinary diagnostics market.", "High margins and profitability sustained.", "Premium valuation from market leadership.", "Innovation drives product expansion.", "Balanced by competition and regulatory risks." ], "target_price_6m": 620, "target_price_12m": 640 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 343, "createdAt": "2026-04-09T05:21:07.773Z", "usage": { "inputTokens": 2024, "outputTokens": 3680, "costUsd": 0.002112 } }, { "id": "cmnr148g304drp658y7f5r5u5", "runId": "cmnr148g104dop6587imwyb4k", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"IDEXX Growth & Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IDXX\",\n \"currency\": \"USD\",\n \"current_price\": 591.84,\n \"target_price_6m\": 625.0,\n \"target_price_12m\": 655.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Dominant market share in companion animal diagnostics provides high-margin recurring revenue streams.\",\n \"Consistent double-digit organic revenue growth driven by increased diagnostic frequency per visit.\",\n \"Best-in-class operating margins and ROE reflect significant competitive moats and scale.\",\n \"Expanding international footprint offers a long runway for instrument placement and testing.\",\n \"Innovation pipeline in fecal and cancer screening supports long-term premium valuation levels.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"CAG Diagnostics recurring revenue\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Veterinary clinic visit frequency\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"International instrument placements\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Software and cloud services adoption\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"R&D efficiency and new test launches\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macroeconomic consumer spending trends\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Multiple compression due to high baseline valuation.\",\n \"Competitive entry in point-of-care diagnostic hardware.\",\n \"Shortage of veterinary professionals limiting clinic capacity.\",\n \"Currency headwinds affecting international revenue translation.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.1,\n \"ebit_margin_target\": 0.33,\n \"wacc\": 0.085,\n \"terminal_multiple\": 35.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 480.0,\n \"prob\": 0.2,\n \"notes\": \"Valuation contracts to historical mean amid slowing pet clinic traffic.\"\n },\n \"base\": {\n \"target_price\": 655.0,\n \"prob\": 0.6,\n \"notes\": \"Steady execution and margin expansion support a premium valuation.\"\n },\n \"bull\": {\n \"target_price\": 780.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated international growth and successful new product launches drive upside.\"\n }\n },\n \"method_notes\": \"Valuation derived from a 10-year DCF and 35x terminal P/E multiple. BUY rating reflects 10.7% total return potential, supported by durable recurring revenue and margin resilience despite premium valuation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "IDEXX Growth & Valuation Model", "risks": [ "Multiple compression due to high baseline valuation.", "Competitive entry in point-of-care diagnostic hardware.", "Shortage of veterinary professionals limiting clinic capacity.", "Currency headwinds affecting international revenue translation." ], "ticker": "IDXX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution and margin expansion support a premium valuation.", "target_price": 655 }, "bear": { "prob": 0.2, "notes": "Valuation contracts to historical mean amid slowing pet clinic traffic.", "target_price": 480 }, "bull": { "prob": 0.2, "notes": "Accelerated international growth and successful new product launches drive upside.", "target_price": 780 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.1, "terminal_multiple": 35, "ebit_margin_target": 0.33 }, "key_drivers": [ { "driver": "CAG Diagnostics recurring revenue", "impact": "HIGH", "direction": "POS" }, { "driver": "Veterinary clinic visit frequency", "impact": "HIGH", "direction": "POS" }, { "driver": "International instrument placements", "impact": "MED", "direction": "POS" }, { "driver": "Software and cloud services adoption", "impact": "MED", "direction": "POS" }, { "driver": "R&D efficiency and new test launches", "impact": "MED", "direction": "POS" }, { "driver": "Macroeconomic consumer spending trends", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation derived from a 10-year DCF and 35x terminal P/E multiple. BUY rating reflects 10.7% total return potential, supported by durable recurring revenue and margin resilience despite premium valuation. Not investment advice.", "current_price": 591.84, "recommendation": "BUY", "thesis_bullets": [ "Dominant market share in companion animal diagnostics provides high-margin recurring revenue streams.", "Consistent double-digit organic revenue growth driven by increased diagnostic frequency per visit.", "Best-in-class operating margins and ROE reflect significant competitive moats and scale.", "Expanding international footprint offers a long runway for instrument placement and testing.", "Innovation pipeline in fecal and cancer screening supports long-term premium valuation levels." ], "target_price_6m": 625, "target_price_12m": 655 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 17387, "createdAt": "2026-04-09T05:21:07.773Z", "usage": { "inputTokens": 2363, "outputTokens": 799, "costUsd": 0.014314 } }, { "id": "cmnr148g304dpp658esuzcfeb", "runId": "cmnr148g104dop6587imwyb4k", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"IDXX\",\"currency\":\"USD\",\"current_price\":591.84,\"target_price_6m\":612,\"target_price_12m\":624,\"recommendation\":\"HOLD\",\"confidence\":0.64,\"thesis_bullets\":[\"Recurring clinic consumables support resilient mid-single to low-double-digit organic growth.\",\"High gross and operating margins show strong competitive moat and pricing power.\",\"EPS and cash flow compounding remains attractive despite modest leverage.\",\"Shares already discount durability, trading at elevated PE and EV/EBITDA multiples.\",\"Limited 12M upside warrants patience unless growth reaccelerates or valuation resets.\"],\"key_drivers\":[{\"driver\":\"Recurring diagnostics consumables\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Instrument installed base growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Reference lab expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"International penetration\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Clinic visit and utilization trends\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Competitive pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"FX and macro sensitivity\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Valuation multiple compression\",\"Slower veterinary visit growth\",\"Competitive assay innovation\",\"Customer capex softness\",\"Regulatory or quality issues\"],\"assumptions\":{\"revenue_cagr_3y\":0.085,\"ebit_margin_target\":0.325,\"wacc\":0.082,\"terminal_multiple\":33},\"scenarios\":{\"bear\":{\"target_price\":505,\"prob\":0.25,\"notes\":\"Clinic demand softens and premium multiple compresses further.\"},\"base\":{\"target_price\":624,\"prob\":0.5,\"notes\":\"Steady consumables growth offsets moderate valuation normalization.\"},\"bull\":{\"target_price\":730,\"prob\":0.25,\"notes\":\"Faster analyzer placements and sustained premium multiple drive upside.\"}},\"method_notes\":\"Blended DCF and EV/EBIT framework using snapshot fundamentals and stated assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. Limited upside versus rich valuation supports HOLD. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Valuation multiple compression", "Slower veterinary visit growth", "Competitive assay innovation", "Customer capex softness", "Regulatory or quality issues" ], "ticker": "IDXX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady consumables growth offsets moderate valuation normalization.", "target_price": 624 }, "bear": { "prob": 0.25, "notes": "Clinic demand softens and premium multiple compresses further.", "target_price": 505 }, "bull": { "prob": 0.25, "notes": "Faster analyzer placements and sustained premium multiple drive upside.", "target_price": 730 } }, "confidence": 0.64, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.085, "terminal_multiple": 33, "ebit_margin_target": 0.325 }, "key_drivers": [ { "driver": "Recurring diagnostics consumables", "impact": "HIGH", "direction": "POS" }, { "driver": "Instrument installed base growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Reference lab expansion", "impact": "MED", "direction": "POS" }, { "driver": "International penetration", "impact": "MED", "direction": "POS" }, { "driver": "Premium valuation multiple", "impact": "HIGH", "direction": "NEG" }, { "driver": "Clinic visit and utilization trends", "impact": "MED", "direction": "POS" }, { "driver": "Competitive pricing pressure", "impact": "MED", "direction": "NEG" }, { "driver": "FX and macro sensitivity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended DCF and EV/EBIT framework using snapshot fundamentals and stated assumptions; no sell-side targets used. Snapshot quote fields kept authoritative. Limited upside versus rich valuation supports HOLD. not investment advice", "current_price": 591.84, "recommendation": "HOLD", "thesis_bullets": [ "Recurring clinic consumables support resilient mid-single to low-double-digit organic growth.", "High gross and operating margins show strong competitive moat and pricing power.", "EPS and cash flow compounding remains attractive despite modest leverage.", "Shares already discount durability, trading at elevated PE and EV/EBITDA multiples.", "Limited 12M upside warrants patience unless growth reaccelerates or valuation resets." ], "target_price_6m": 612, "target_price_12m": 624 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0379fa7c3d6a03200069d75a0e3f948197ae23d0bbb31508f0", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 34899, "createdAt": "2026-04-09T05:21:07.773Z", "usage": { "inputTokens": 2297, "outputTokens": 2096, "costUsd": 0.033364 } }, { "id": "cmnr148g304dsp6584hxyu7ec", "runId": "cmnr148g104dop6587imwyb4k", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Two-Stage DCF Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"IDXX\",\n \"currency\": \"USD\",\n \"current_price\": 591.84,\n \"target_price_6m\": 605,\n \"target_price_12m\": 620,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Leading vet diagnostics provider with strong recurring revenue model\",\n \"10% revenue growth supported by pet healthcare secular trends\",\n \"51x forward P/E leaves little room for error at current levels\",\n \"High returns on capital and cash flow support innovation\",\n \"International expansion and new products offer growth potential\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pet healthcare spending growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Recurring consumables revenue\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product innovation pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Margin expansion opportunities\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Valuation multiple contraction\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Economic downturns affecting vet visits\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competition from new entrants\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Global market expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Multiple compression due to high current valuation\",\n \"Slower than expected revenue growth in mature markets\",\n \"Increased competition in veterinary diagnostics\",\n \"Macroeconomic pressures reducing pet owner spending\",\n \"Currency fluctuations in international revenue\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.09,\n \"ebit_margin_target\": 0.325,\n \"wacc\": 0.085,\n \"terminal_multiple\": 35\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 480,\n \"prob\": 0.3,\n \"notes\": \"Growth decelerates amid economic weakness and margin pressure.\"\n },\n \"base\": {\n \"target_price\": 620,\n \"prob\": 0.5,\n \"notes\": \"Consistent execution delivers mid-teens earnings growth.\"\n },\n \"bull\": {\n \"target_price\": 750,\n \"prob\": 0.2,\n \"notes\": \"Accelerated adoption of new technologies boosts growth.\"\n }\n },\n \"method_notes\": \"Two-stage DCF with 9% revenue CAGR, 32.5% EBIT margin target, 8.5% WACC and 35x terminal multiple. Balanced growth outlook and rich valuation support HOLD rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Two-Stage DCF Model", "risks": [ "Multiple compression due to high current valuation", "Slower than expected revenue growth in mature markets", "Increased competition in veterinary diagnostics", "Macroeconomic pressures reducing pet owner spending", "Currency fluctuations in international revenue" ], "ticker": "IDXX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Consistent execution delivers mid-teens earnings growth.", "target_price": 620 }, "bear": { "prob": 0.3, "notes": "Growth decelerates amid economic weakness and margin pressure.", "target_price": 480 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption of new technologies boosts growth.", "target_price": 750 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.09, "terminal_multiple": 35, "ebit_margin_target": 0.325 }, "key_drivers": [ { "driver": "Pet healthcare spending growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring consumables revenue", "impact": "HIGH", "direction": "POS" }, { "driver": "Product innovation pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Margin expansion opportunities", "impact": "MED", "direction": "POS" }, { "driver": "Valuation multiple contraction", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic downturns affecting vet visits", "impact": "MED", "direction": "NEG" }, { "driver": "Competition from new entrants", "impact": "MED", "direction": "NEG" }, { "driver": "Global market expansion", "impact": "MED", "direction": "POS" } ], "method_notes": "Two-stage DCF with 9% revenue CAGR, 32.5% EBIT margin target, 8.5% WACC and 35x terminal multiple. Balanced growth outlook and rich valuation support HOLD rating. Not investment advice.", "current_price": 591.84, "recommendation": "HOLD", "thesis_bullets": [ "Leading vet diagnostics provider with strong recurring revenue model", "10% revenue growth supported by pet healthcare secular trends", "51x forward P/E leaves little room for error at current levels", "High returns on capital and cash flow support innovation", "International expansion and new products offer growth potential" ], "target_price_6m": 605, "target_price_12m": 620 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "20d44a9f-9839-9ae0-a9a3-5948b69038f4", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20718, "createdAt": "2026-04-09T05:21:07.773Z", "usage": { "inputTokens": 2635, "outputTokens": 3741, "costUsd": 0.06402 } } ] } }